TDT-067: Phase II data

In an open-label Phase II trial in 51 patients, TDT-067 met the primary endpoint of a undisclosed mycological cure rate at 14 weeks, with a 90% cure rate. The cure rate was 38% at 48 weeks. TDT-067 wa...